Académique Documents
Professionnel Documents
Culture Documents
Diabetes y Sndrome
Metablico 2012
Dr Ramiro Sanchez
Presidente de LASH
Auspiciantes :
Presidencia :
Consultores Invitados :
Mesas de Trabajo
# 1.- Epidemiologa de la HA, el SM y la DMT2 en Latino Amrica, Que tan
juntos, que tan independientes
Coordinadores: Myrian Ayala (Paraguay), Margarita Diaz (Uruguay)
# 2.- Poblaciones especiales en riesgo en SM, DM e HA: gestacin, niez y
adolescencia, adultos mayores
Coordinadores: Leonardo Cobos (Chile), Alfonso Brice Moncloa (Per)
# 3.- Papel de la gentica y la epigentica en la creciente prevalencia de HA,
SM y DM en Latino Amrica
Coordinadores: Jose Parra Carrillo (Mexico), Fernando Lizcano (Colombia)
# 4.- Utilidad en la poblacin Latinoamericana de los criterios diagnsticos y
clasificaciones internacionales de HA, SM y DM. Necesitamos definir los
criterios ms apropiados para nuestra realidad ?
Coordinadores: Fernando Lanas (Per), Isaac Sinay (Argentina)
Mesas de Trabajo
# 5.- Cambios teraputicos en los hbitos de vida. Cundo y como
implementarlos ?
Coordinadores: Ivan Dario Sierra (Colombia), Ernesto Peraherrera (Ecuador)
Participantes mesa 1:
Maria Eugenia Casanova (Colombia)
Yan Carlos Duarte (Ecuador)
Juan Jose Rey (Colombia)
Gregorio Sanchez (Colombia)
Aristides Sotomayor (Colombia)
Henry Garcia (Colombia)
Jannes Buelvas (Colombia)
Belkis Pineda (Colombia)
Hernan Pratt (Chile)
Participantes mesa 3:
Alonso Merchan (Colombia)
Felix Medina (Peru)
Boris Vesga (Colombia)
Erick Hernandez (Colombia)
Sergio Alvernia (Colombia)
Juan Mauricio Cardenas (Colombia)
Oscar Medina (Colombia)
Participantes mesa 2:
Helard Manrique (Peru)
Livia Machado (Venezuela)
Enrique Melgarejo (Colombia)
Jesus Alirio Pea (Colombia)
Luis Hernando Garcia (Colombia)
Jhon Feliciano (Colombia)
Isabel Jauregui (Colombia)
Patricia Rodriguez (Colombia)
Participantes mesa 4:
Daniel Piskorz (Argentina)
Agustin Ramirez (Argentina)
Carlos Ponte (Venezuela)
Alvaro Marquez (Colombia)
Carlos Cure (Colombia)
Fernando Manzur (Colombia)
Diego Higuera (Colombia)
Gilberto Castillo (Colombia)
Participantes mesa 5:
Helena Smith (Brasil)
Juan Carlos Uribe (Colombia)
Luz Ximena Martinez
(Colombia)
John Duperly (Colombia)
Fabio Bolivar (Colombia)
Peggy Freire (Ecuador)
Santiago Garcia (Ecuador)
Participantes mesa 7:
Alejandro Yenes (Chile)
Edgar Arcos (Colombia)
Maritza Perez (Colombia)
Tatiana espinosa (Colombia)
Gustavo Parra (Colombia)
Participantes mesa 6:
Jesus Rodriguez (Colombia)
Ricardo Vargas (Chile)
Dora Ines Molina (Colombia)
Solon Navarrete (Colombia)
Luis Echeverria (Colombia)
Roberto Medina (Mexico)
Carlos Francisco Jaramillo (Colombia)
Participantes mesa 8:
Miguel Pasquel (Ecuador)
Raul Villar (Chile)
Javier Martinez (Colombia)
Jose Luis Accini (Colombia)
Eduardo Villareal (Colombia)
Carlos Calderon (Colombia)
Harold Miranda (Colombia)
Sergio Jaramillo (Colombia)
5.0
Cuba
4.7 n/d
Bolivia
7.2
Jamaica
13.4
Brazil
7.6
Mexico
8.6
Chile
3.9
Paraguay
6.2
Colombia
7.3
Uruguay
7.0
Venezuela
4.4 *
4.7
WHO 1980
WHO1985
ADA-WHO 1997
n/d no data
Uruguay
2005
Venezuela
0
20
40
60
80
% of Rurality
Source: CEPAL (2008) Panorama Socioeconmico de Amrica Latina 2008
PRESION ARTERIAL
1 The seventh report of the Joint National Committee on prevention, detection, evaluation, and
treatment of high blood pressure. The JNC 7 Report. JAMA 2003; 289:25602572.
2 The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension
(ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 25:11051187.
4 Latin American Consensus on Arterial Hypertension. J Hypertens [Spanish ed.] 2001; 6:01110.
6 ACCF/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American
College of Cardiology Foundation Task Force on Clinical Expert Consensus documents developed in
collaboration with the American Academy of Neurology, American Geriatrics Society, American Society
for Preventive Cardiology, American Society of Hypertension, American Society of Nephrology,
Association of Black Cardiologists, and European Society of Hypertension. J Am Coll Cardiol. 2011 May
17;57(20):2037-114
7 National Institute for Health and Clinical Excellence. Hypertension: clinical management of primary
hypertension in adults (update). (Clinical guideline 127.) 2011. http://guidance.nice.org.uk/CG127.
Recomendaciones para la
determinacin Domiciliaria de PA
Empleo de apartos automticos
validados
Sentado, luego de descansar y mejor a la
maana y al atardecer
Valor (mmHg)
Optima
<120/80
Normal
120/80-129/84
Normal Alta
130/85 139/89
Hipertensin
Grado 1
140-159/90-99
Grado 2
160-179/100-109
Grado 3
180/110
140/<90
>150/>90
Valor (mmHg)
Optima
<120/80
Normal
120/80-129/84
Normal Alta
130/85 139/89
Hipertensin
Grado 1
140-159/90-99
Grado 2
160-179/100-109
Grado 3
180/110
140/<90
>150/>90
VARIABLE
CONTINUA
NORMAL
PERO
MAYOR
RIESGO
QUE LA
OPTIMA
Valor (mmHg)
Optima
<120/80
Normal
120/80-129/84
Normal Alta
130/85 139/89
Hipertensin
Grado 1
140-159/90-99
Grado 2
160-179/100-109
Grado 3
180/110
140/<90
>150/>90
BUSCAR
CAIDA
ORTOSTATICA
EVITAR
< 130/65
Risk stratification in subjects with metabolic syndrome (MS), hypertension and diabetes type 2 (DM2)
Normotension
Other risk factors or diseases
Optimal
Normal
Hypertension
High normal
Grade 1
Grade 2
Grade 3
No RF
Mean risk
Mean risk
Mean risk
Low added
risk
Moderate
added risk
High added
risk
Low added
risk
Low added
risk
Low added
risk
Moderate
added risk
Moderate
added risk
Very high
added risk
Moderate
added risk
Moderate
added risk
High added
risk
High added
risk
High added
risk
Very high
added risk
High added
risk
High added
risk
Very high
added risk
Very high
added risk
Very high
added risk
Very high
added risk
SINDROME METABOLICO
1.-Harmonizing the Metabolic Syndrome : A Joint Interim Statement of the International Diabetes
Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute;
American Heart Association; World Heart Federation; International Atherosclerosis Society; and
International Association for the Study of Obesity, Circulation 2009, 120:1640-1645
2.- Definition, diagnosis and classification of diabetes mellitus and its complications, part 1: diagnosis and
classification of diabetes mellitus provisional report of a WHO consultation.Diabet Med. 1998;15:539
553.
3.- National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment
of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol
Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol
in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106:31433421.
4.- IDF Epidemiology Task Force Consensus Group. The metabolic syndrome: a new worldwide definition.
Lancet. 2005; 366:1059 1062.
INELUDIBLE
Obesidad Central
Permetro de cintura= 94,
88 cm
Prediabetes
Criterios diagnsticos
Glucemia alterada en ayunas 100/110 - 125 mg/dl en dos ocasiones2*
Tolerancia alterada a glucosa oral 140 199 mg/dl en dos ocasiones
luego de 75 g de glucosa en 375 cl de agua
1.- Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert
Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997;20:1183
1197
2.- Expert Committee on the Diagnosis and Classification of Diabetes Mellitus2, the Expert
Committee on the Diagnosis and Classification of Diabetes Mellitus. Follow-up report on the
diagnosis of diabetes mellitus. Diabetes Care 2003;26: 31603167
* Cuando no haya dificultades la prueba de Carga Oral deber relizarse luego de la primera
glucemia alterada en ayunas
Diabetes
Criterios diagnsticos
Glucemia en ayunas126 mg/dl en dos ocasiones
200 mg/dl 120 minutos despus de la carga de glucosa (TTOG)
200 mg/dl en cualquier momento asociada a sntomas
Diagnosis and Classification of Diabetes Mellitus American Diabetes Association,
Diabetes Care, Volume 34, Supplement 1, January 2011, S62-S69
Diabetes
126
GAA
GAA + TAG
Normalidad o
Sindrome
Metablico
TAG
100/110
140
200
American Diabetes Association: Standards of Medical Care in Diabetes, 2010. Diabetes Care 2010;
33(Suppl 1): S4 S10.
2.
Rutter MK y col, Blood pressure, lipids and glucose in Type 2 diabetes: how low should we go ? Re disccovering personalized care. European Heart Journal 32 (18): 2247 2245, Sept 2011.
3.
4.
5.
Bangalore S y col, Blood pressure targets in subjects with Type 2 diabetes mellitus / impaired fasting
glucose: observation from traditional and bayesian random effects meta analysis of randomized
trials. Circulation 2011; 123: 2799 2810
6.
EFICACIA
ANTIHIPERTENSIVA
CARDIOPROTECTORA
PROTECCIN RENAL
PROTECCION CEREBROVASCULAR
SI SE INICIA MONOTERAPIA
POR SU EFECTO NEFROPROTECTOR
HOPE, JAMA 2001; 286:1882-1885
ONTARGET, N Engl J Med 2008; 358: 1547-1559
MEJOR
TOLERADOS
EFICACIA
ANTIHIPERTENSIVA
CARDIOPROTECTORA
PROTECCIN RENAL
PROTECCION CEREBROVASCULAR
BETA
BLOQUEANTES
Si no acceso a PA objetivo
Diurtico Tiazdico
(Indapamida, Clortalidona o Hidroclorotiazida)
Muchas Gracias